Silencing or Stimulation? siRNA Delivery and the Immune System
- 15 July 2011
- journal article
- review article
- Published by Annual Reviews in Annual Review of Chemical and Biomolecular Engineering
- Vol. 2 (1), 77-96
- https://doi.org/10.1146/annurev-chembioeng-061010-114133
Abstract
Since its inception more than a decade ago, the field of short interfering RNA (siRNA) therapeutics has demonstrated potential in the treatment of a wide variety of diseases. The power behind RNA interference (RNAi) therapy lies in its ability to specifically silence target genes of interest. As more biological data have become available, it has become evident that, in addition to mediating RNAi, siRNA molecules have the potential to potently induce the innate immune system. One of the significant challenges facing the field today is the differentiation between therapeutic effects caused by target-specific, RNAi-mediated gene silencing and those caused by nonspecific stimulation of the innate immune system. Unless appropriate experimental measures are taken to control for RNA-induced immunostimulation, genetic manipulation can be confused with immune activation. This review attempts to provide an accessible background in siRNA-relevant immunology and to highlight the ways in which siRNA can be engineered to avoid or provoke an innate immune response.Keywords
This publication has 100 references indexed in Scilit:
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Rational Design of Immunostimulatory siRNAsMolecular Therapy, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Pattern Recognition Receptors and InflammationCell, 2010
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responsesNature Biotechnology, 2009
- Drug Delivery–mediated Control of RNA ImmunostimulationMolecular Therapy, 2009
- A novel high‐throughput cell‐based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug deliveryBiotechnology & Bioengineering, 2009
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Pathogen Recognition and Innate ImmunityCell, 2006
- Induction of an interferon response by RNAi vectors in mammalian cellsNature Genetics, 2003